An interventional study of reSept ASD Occluder in Heart Septal Defect, Heart Septal Defects, Atrial and Heart Defects, Congenital, sponsored by atHeart Medical. Active, not recruiting at 32 sites in 4 countries. Open to participants aged Up to 84 Years. Per ClinicalTrials.gov, last updated 2025-05-07.
Sponsored by atHeart Medical · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Heart Septal Defects, Atrial with a site in United States — 3 open to participants now, 5 under way, none of them phase 3. Heart Septal Defects, Atrial · United States.
Among the 24 studies in Heart Septal Defects, Atrial with a site in United States, this one is the 5th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2021, is one of 7 with no phase, and was the 19th registered.
84 studies on the registry are indexed under Heart Septal Defects, Atrial; 21 are open to participants now.
Browse Heart Septal Defects, Atrial studies →3 of the 24 studies in Heart Septal Defects, Atrial with a site in United States are open now. Recruiting first, the newest first:
Tufts Medical Center · Sites in United States
Ages 18+
Abbott Medical Devices · Sites in United States, Denmark, Estonia and 7 more countries
Philips Clinical & Medical Affairs Global · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Heart Septal Defects, Atrial studies recruiting now, 4 set no upper age limit and 3 stop at 75 or younger; 5 take children under 18; none take healthy volunteers.
This study: Up to 84 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 6 · Phase 4 1
First in 2002; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 100 across 50 interventional studies indexed under Heart Septal Defects, Atrial.
Median enrollment 155 across the 16 interventional studies, 100 across the 8 observational. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 24 have an industry lead sponsor. The 10 most frequent:
atHeart Medical is the lead sponsor of 2 studies on the registry; none are open to participants now.
atHeart Medical has 2 studies filed under Heart Septal Defects, Atrial — fewer than ten, so there is no comparison to draw.
1 of the studies in Heart Septal Defects, Atrial with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04591392atHeart MedicalSafety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Heart Septal Defects, Atrial with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evaluation of the safety and efficacy of the reSept ASD Occluder to treat patients with clinically significant secundum atrial septal defect
Prospective, three-stage, single arm, multi-site, clinical investigation evaluating the safety and efficacy of the reSept ASD Occluder in treating clinically significant secundum ASD. Outcomes/endpoints of the clinical investigation will be compared with established performance goals for FDA approved transcatheter secundum ASD occluders.
84 studies on the registry are indexed under Heart Septal Defects, Atrial; 21 are open to participants now.
This study's planned enrollment of 250 is above the median of 100 across 50 interventional studies indexed under Heart Septal Defects, Atrial.
Browse Heart Septal Defects, Atrial studies →atHeart Medical is the lead sponsor of 2 studies on the registry; none are open to participants now.
Compared within Heart Septal Defects, Atrial, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Septal Defects. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All responses must be Yes to be eligible:
Exclusion Criteria:
All responses must be No to be eligible:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASD closure with the reSept ASD Occluder
Device: reSept ASD Occluder
Transcatheter closure of secundum ASD using a permanent implant
Number of Subjects with 12-Month Composite Clinical Success
1. Clinically effective ASD closure, defined as no residual ASD or clinically insignificant residual ASD as determined by core laboratory review; and 2. No re-intervention to treat the defect; and 3. No device or procedure related serious adverse event.
Time frame: 12 months
Number of Subjects with CEC adjudicated Device- or Procedure-related SAEs
Incidence of subjects experiencing one or more serious device- or procedure related adverse events through the 12 month follow up visit, as adjudicated by the Clinical Events Committee (CEC)
Time frame: 12 months
ASD Closure Success among Technical Success Subjects
Assessment of device performance will include closure success, among subjects that were technical successes (i.e. successful placement and release of the reSept ASD Occluder at the ASD), defined as no residual ASD or clinically insignificant residual ASD determined by echocardiography. Assessment of closure success at each follow up through the 12-month follow up will be assessed by TTE.
Time frame: 1 month, 6 months and 12 months
Number of Subjects with Device- or Procedure-related AEs
Incidence of subjects experiencing one or more non serious device- or procedure-related adverse events through the 12-month follow up visit.
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2021 (actual). Primary completion is estimated for Mar 2027, 72 months after the start.
Of 19 interventional studies with no phase under Heart Septal Defects, Atrial, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 56. This study's planned 72 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Heart Septal Defects, Atrial →
atHeart Medical